Last reviewed · How we verify
Palbociclib PD-0332991
Palbociclib is a CDK4/6 inhibitor that works by blocking the activity of cyclin-dependent kinases 4 and 6, which are involved in cell cycle progression.
Palbociclib is a CDK4/6 inhibitor that works by blocking the activity of cyclin-dependent kinases 4 and 6, which are involved in cell cycle progression. Used for Hormone receptor-positive, HER2-negative breast cancer.
At a glance
| Generic name | Palbociclib PD-0332991 |
|---|---|
| Also known as | Ibrance |
| Sponsor | GBG Forschungs GmbH |
| Drug class | CDK4/6 inhibitor |
| Target | CDK4/6 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting CDK4/6, palbociclib slows down the growth and division of cancer cells. This can help to slow the progression of certain types of cancer. Palbociclib is often used in combination with other medications to treat hormone receptor-positive, HER2-negative breast cancer.
Approved indications
- Hormone receptor-positive, HER2-negative breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Leukopenia
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) (PHASE2)
- Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma (PHASE1)
- Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) (PHASE2)
- A Study of the Use of Text Message Reminders to Take Palbociclib (NA)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial (PHASE2)
- Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |